ALSO NOTED: Glaxo's Veramyst wins approval; Insmed reports positive Phase II data;and much more...

> The FDA has approved GlaxoSmithKline's Veramyst Nasal spray for adults and children over the age of 2. Veramyst is designed to target nasal allergy symptoms such as sneezing, congestion and runny nose. It's the first regulatory OK for the therapy, which is also being reviewed in Europe, Japan and other markets. Release

> The FDA has approved CSL Behring's Humate-P for a bleeding disorder known as von Willebrand disease. Report

> The FDA has approved SoloSTAR, Sanofi-Aventis' disposable insulin pen for the treatment of hyperglycemia in people with type 1 or type 2 diabetes. Report

> Insmed has announced positive results from a Phase II investigator-sponsored clinical study of IPLEX in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome. Release

> Duramed's Enjuvia has won two new FDA approvals. Release

> Chutes & Ladders: Anaptys Biosciences has named Tom Smart to the newly created position of chairman and chief executive officer. Smart is the former chief business officer at XOMA. Release

> Varian is reorganizing its scientific instruments business, cutting up to 60 jobs as it consolidates facilities. Report

And Finally… Drugs that adjust dopamine levels in the brain greatly affect how people react to success and failure, according to research presented at the American Academy of Neurology's 59th Annual Meeting in Boston. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.